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Abstract 
Topical administration permits targeted, sustained delivery of therapeutics to human skin. Delivery to the skin, 
however, is typically limited to lipophilic molecules with molecular weight of < 500 Da, capable of crossing the 
stratum corneum. Nevertheless, there are indications protein delivery may be possible in barrier deficient skin, 
a condition found in several inflammatory skin diseases such as psoriasis, using novel nanocarrier systems.  
Methods: Water in water thermo-nanoprecipitation; dynamic light scattering; zeta potential measurement; 
nanoparticle tracking analysis; atomic force microscopy; cryogenic transmission electron microscopy; UV 
absorption; centrifugal separation membranes; bicinchoninic acid assay; circular dichroism; TNFα binding 
ELISA; inflammatory skin equivalent construction; human skin biopsies; immunohistochemistry; fluorescence 
microscopy; western blot; monocyte derived Langerhans cells; ELISA 
Results: Here, we report the novel synthesis of thermoresponsive nanogels (tNG) and the stable encapsulation 
of the anti-TNFα fusion protein etanercept (ETR) (~150 kDa) without alteration to its structure, as well as 
temperature triggered release from the tNGs. Novel tNG synthesis without the use of organic solvents was 
conducted, permitting in situ encapsulation of protein during assembly, something that holds great promise for 
easy manufacture and storage. Topical application of ETR loaded tNGs to inflammatory skin equivalents or tape 
striped human skin resulted in efficient ETR delivery throughout the SC and into the viable epidermis that 
correlated with clear anti-inflammatory effects. Notably, effective ETR delivery depended on temperature 
triggered release following topical application.  
Conclusion: Together these results indicate tNGs hold promise as a biocompatible and easy to manufacture 
vehicle for stable protein encapsulation and topical delivery into barrier-deficient skin. 
Key words: thermoresponsive-nanogel, topical, anti-inflammatory therapy, etanercept, skin equivalents. 
Introduction 
Topical administration permits highly targeted, 
sustained delivery of therapeutics to the skin whilst 
circumventing many issues associated with systemic 
administration such as first pass metabolism and off 
target drug distribution. However, the outermost 
layer of human skin - the stratum corneum (SC) - is a 
highly effective barrier that prevents the penetration 
of all but small (< ~500 Da) and moderately lipophilic 
molecules.[1, 2] Nonetheless, several non-invasive 
techniques that facilitate the passage of hydrophilic 
macromolecules into or through skin have been 
tested. These include chemical penetration enhancers, 
[3-5] physical disruptions of the SC,[6-8] skin 
penetrating peptides [9-11] and a number of 
nanoparticles.[12-17] However, their ability to deliver 









preserving the protein’s biological activity and 
avoiding skin irritancy, remains an unattained goal. 
Topical delivery of therapeutic macromolecules 
may present new therapeutic options for skin 
disorders. Common inflammatory skin diseases such 
as psoriasis and atopic dermatitis (AD) for instance 
may benefit from local, non-systemic applications of 
the ever-growing list of anti-inflammatory biologicals. 
This would circumvent the often severe side-effects 
associated with their systemic applications and would 
likely reduce the dose required of these highly 
expensive therapies.  
Therapeutically useful topical protein delivery 
strategies must effectively deliver their cargo past the 
SC whilst preserving the protein's structure / 
biological activity, without damage to the existing 
skin barrier or induction of irritancy and cellular 
toxicity. These points limit the potential usefulness of 
some of the aforementioned skin delivery strategies 
for biomacromolecules. For example, though physical 
methods like sonoporation and microneedle patches 
can effectively deliver proteins into skin, the inherent 
energy involved can lead to conformational changes 
detrimental to the therapeutic activity of proteins as 
well as skin irritancy.[18]  
Our groups have intensively investigated the 
potential of thermoresponsive nanogels (tNGs) as 
cutaneous penetration enhancers. They consist of 
nanometer scale polymeric networks incorporating 
thermoresponsive polymers that bestow 
environmental responsiveness to physiologically 
relevant changes in temperature.[19, 20] While they 
are swollen with water below their cloud point 
temperature (Tcp), the thermoresponsive polymers of 
the tNGs undergo a reversible transition in water 
solubility when exposed to greater temperatures, 
resulting in gel shrinking and the expulsion of water. 
A broad range of cargoes may be encapsulated within 
tNG and then released from these in a temperature 
sensitive manner. 
The synthesis strategy of tNG has to take into 
consideration the compatibility with biologically 
active macromolecules, while retaining their 
structural integrity and biological activity. The 
nanoprecipitation technique is the method of choice 
for in situ protein encapsulation due to the absence of 
extensive shear forces, sonication or heating. Organic 
solvents such as dimethyl sulfoxide, acetonitrile, and 
acetone have been used as solvent components for 
protein encapsulation during nanoprecipitation 
[21-23]. Yet, the presence of such organic solvents 
might cause structural alterations to the protein and 
cause immunogenic responses owing to the presence 
of residual solvents. Here, we present a novel and 
universal technique for the fabrication of tNG under 
mild conditions that does not require the utilisation of 
organic solvents, surfactants, or elevated 
temperatures that would otherwise denature proteins. 
Here, the conventional method of nanoprecipitation, 
in which solvents and non-solvents are utilised for the 
particulate precipitation of polymeric precursors, was 
modified to allow an aqueous buffer solution to serve 
as both solvent and non-solvent. For this, dendritic 
polyglycerol (dPG) and linear thermoresponsive 
polyglycerol (tPG) served as building blocks for the 
fabrication of the tNGs. These, alongside the 
previously reported poly(N-isopropylacrylamide) 
(pNIPAM) based tNGs, were used to encapsulate 
etanercept (ETR). ETR is a fusion protein of the 
human TNFα receptor and the Fc tail of IgG1 (Mw 
~150 kDa) approved for the treatment of psoriasis and 
arthritis by subcutaneous injection.[24, 25] Notably, 
the efficacy of human-based biologicals such as ETR 
cannot be easily tested in animals due to 
immunological responses. Hence, we utilized a 
previously established in vitro model of TNFα 
mediated skin inflammation - a key feature of 
inflammatory diseases such as psoriasis and chronic 
atopic dermatitis—and further characterise it for use 
as a novel preclinical test system.[26-28] With this and 
ex vivo human skin, we demonstrate the effective 
topical delivery of ETR to the viable epidermis (VE) 
by tNGs, followed by clear anti-inflammatory actions. 
We also demonstrate the necessity for triggered 
release of proteins from tNGs for their delivery into 
the VE following topical application. Furthermore, 
studies with immune cells akin to those found 
resident with human skin showed no toxic or 
immunogenic potential from the ETR loaded 
tNGs.[29] 
Materials and Methods 
Materials 
Commercially available chemicals from 
standardised sources were used as delivered. Solvents 
were purchased as reagent grade and distilled if 
necessary. Anhydrous solvents were either purchased 
as ultra-dry solvent (Acros Organics®) or obtained 
from MBRAUN SPS 800 solvent purification system 
(Garching, Germany). Water was purified by a 
Millipore water purification system. Dendritic 
polyglycerol (dPG) with average Mw of 10 kDa (PDI = 
1.27) was purchased from Nanopartica GmbH (Berlin, 
Germany). The crosslinking reagent (1R,8S,9s)- 
bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) 
carbonate (BCN) was purchased from Synaffix (AE 
Oss, Netherlands).[30] Amine functionalization of 
dPG was performed according to a previously 
reported protocol [31]; degrees of functionalization 





for dPG-Ac10% and dPG-BCN8% are given as a 
percentage of the total dPG hydroxyl groups (~ 135 
hydroxyl groups for 10 kDa dPG). Glycidyl methyl 
ether (GME) (85%) and ethyl glycidyl ether (EGE) 
(98%; both TCI Europe, Eschborn, Germany) were 
dried over CaH2, distilled, and stored over molecular 
sieves (5 Å). Indodicarbocyanine (IDCC) was 
purchased from Lumiprobe GmbH (Hannover, 
Germany). Synthesis of tPG was performed according 
to a previously reported procedure with slight 
adjustments.[32] Bovine Collagen I (“PureCol”) was 
purchased from Advanced Biomatrix (San Diego, 
USA). Transwell cell culture inserts (3 µm pore 
molecular weight cut-off (MWCO)) were purchased 
from BD Biosciences (Heidelberg, Germany). 
Recombinant TNFα was purchased from Affymetrix 
eBiosciences GmbH (Frankfurt, Germany). For 
primary antibodies, anti-TNFα (ab183896), anti-TSLP 
(ab47943), and anti-ICAM1 (ab53013) were purchased 
from abcam (Cambridge, UK). For secondary 
antibodies, anti-IgG rabbit tagged with alexa 594 
(ab10080) was purchased from abcam (Cambridge, 
UK), and anti-IgG rabbit tagged with 
horseradish-peroxidase (#7074) was purchased from 
Cell Signaling (Frankfurt/Main, Germany).  
Synthesis and characterization of nanogels 
The synthesis of pNIPAM-based nanogels 
(tNG_pNIPAM) was performed according to a 
previously reported method.[33] Briefly, pNIPAM (66 
mg), acrylated dendritic polyglycerol (dPG-Ac10%) (33 
mg), sodium dodecyl sulfate (SDS) (1.8 mg), and 
ammonium persulfate (APS) (2.8 mg) were dissolved 
in 5 mL of distilled water. To produce fluorescently 
labelled nanogels, indodicarbocyanine (IDCC) 
conjugated dPG-Ac10% (3 mg) was allowed to react 
with the unlabeled crosslinker. Argon was bubbled 
into the reaction mixture for 15 min, followed by 
stirring under an argon atmosphere for another 15 
min. The reaction mixture was then transferred into a 
water bath at 68 °C. Polymerization was activated 
after 5 min by addition of a catalytic quantity of 
N,N,N′,N′-tetramethylethane-1,2-diamine (TEMED; 
120 µL). The mixture was stirred at 500 rpm for at 
least 4 h. 
For the synthesis of tPG-based nanogels 
(tNG_tPG), dPG-BCN8% (10 mg) and di-azide 
functionalised tPG (tPG-(N3)2) (20 mg) (and 0.3 mg 
ETR for in situ encapsulation) were mixed in 1 mL 
phosphate buffered saline (PBS), cooled in an ice bath 
and injected by syringe into 20 mL of PBS at 37 °C. 
The mixture was stirred for 6 h. Unreacted alkynes 
were quenched with azidopropanol or, alternatively, 
IDCC-N3. The tNGs products were purified by 
dialysis (MWCO 50 kDa) in water for at least two 
days. In addition, IDCC labelled nanogels were 
purified by a Sephadex G25 fine column (GE 
Healthcare Berlin, Germany). The absence of a free 
dye was verified by thin layer chromatography (TLC) 
(Merck aluminium sheets with silica (corn size 60) and 
fluorescence marker F254). 
The resulting tNG_pNIPAM was then 
lyophilised to yield a white solid. The tNG_tPG were 
stored as a highly concentrated solution. In total, three 
batches were produced and characterised 
independently. 
Dynamic light scattering (DLS) and zeta potential 
Size distribution and zeta potential of tNGs were 
measured at various temperatures by dynamic light 
scattering (DLS) using a Zetasizer Nano-ZS 90 
(Malvern, UK) equipped with a He–Ne laser (λ = 633 
nm) under scattering angle of 173°. For equilibration, 
samples with the concentration of 1 mg/mL were 
maintained at the desired temperature for 5 min prior 
to testing. Particle size distributions are given as the 
average of three measurements from intensity 
distribution curves. As DLS measurements of the 
nanogels were monomodal in distribution, with 
autocorrelation functions showing a single 
exponential decay, the hydrodynamic diameters are 
reported from the intensity distribution curves. 
Nanoparticle tracking analysis (NTA) 
Size, particle concentration, and approximate 
Mw of the tNGs were measured by NTA using a 
Nanosight NS500 (Malvern Instruments, Malvern, 
UK). The samples were prepared by diluting 1000 
times the solution prepared for DLS measurements. 
Particle sizes, concentration, and Mw are given as the 
average of three measurements. 
Atomic force microscopy (AFM) 
AFM measurements were recorded on a 
MultiMode 8 AFM equipped with a Nanoscope V 
controller (Veeco Instruments, Santa Barbara, 
California). The data were analyzed using NanoScope 
Analysis 1.3 software and statistical analyses were 
performed on 10 µm x 10 µm images. The tNGs 
aqueous solutions (2.5 mg/mL) were air dried on a 
Mica sheet. Samples were measured with Nano World 
tips, Soft Tapping Mode (SNK-10), with resonance 
frequency of 56-75 kHz and force constant of 0.24 
N/m. 
Cryogenic transmission electron microscopy 
(cryo-TEM)  
A droplet (5 μL) of the sample solution was 
placed on hydrophilized (plasma treatment using a 
BALTEC MED 020 device (Leica Microsystems, 
Wetzlar, Germany), perforated carbon filmed grids 





(Quantifoil Micro Tools GmbH, Jena, Germany). The 
excess fluid was blotted off to create an ultra-thin 
layer (typical thickness of 200-300 nm) of the solution 
that spans the holes of the supporting film. Samples 
were then immediately vitrified by propelling the 
grids into liquid ethane at its freezing point (-184 °C). 
The vitrified sample grids were transferred under 
liquid nitrogen, by the use of a Gatan (Pleasanton,CA, 
USA) cryo-holder (Model 626), into a Tecnai F20 TEM 
(FEI company, Oregon, USA) equipped with a field 
emission gun (FEG) and operated under a 160 kV 
acceleration voltage. Microscopy was carried out at 
-175 °C sample temperature using the microscope’s 
low dose protocol at calibrated primary 
magnifications of 5k and 29k. The defocus was set to 
9.81 µm (29k). Images were recorded on a 4k-Eagle 
CCD camera (FEI Company, Oregon, USA) at 2k 
resolution (binning 2). 
Cloud point temperature (Tcp) determination by 
UV-Visible measurement 
The Tcp were measured on a Lambda 950 
UV/Vis/NIR spectrometer, Perkin Elmer Life and 
Analytical Sciences (Connecticut, USA) equipped 
with a temperature-controlled, six-position sample 
holder. Solutions of tNG in PBS (pH 7.4) were heated 
at 0.2 °C/min while monitoring both the transmission 
at 500 nm (1 cm path length) and the solution 
temperature (from 18 to 55 °C), as determined by the 
internal temperature probe. The Tcp of each nanogel 
was defined as the temperature at the inflection point 
of the normalised transmission curves. 
Encapsulation and release studies 
For protein encapsulation of ETR or fluorescein 
isothiocyanate labelled bovine serum albumin 
(FITC-BSA), tNG_pNIPAM or tNG_tPG nanogels (10 
mg/mL) were swollen in a protein solution (1 
mg/mL) for 24 h at 4 °C. The in-situ encapsulation of 
ETR was performed as a proof of concept and used for 
its structural characterization. For experiments on 
skin models, proteins were encapsulated post 
synthesis by swelling tNGs in protein solutions. The 
solutions were purified using Vivaspin 300 kDa for 
FITC-BSA or Vivaspin 1000 kDa for ETR (according to 
the manufacturer’s instructions; Sartorius AG, 
Göttingen, Germany). Protein concentrations in the 
resulting exudates were then determined by UV 
measurements for FITC-BSA and by Bradford assay 
for ETR. The Bradford assay was conducting 
according to standard procedure: 100 mg Coomassie 
Brilliant Blue G250 was dissolved in 50 mL of ethanol, 
to which 100 mL of concentrated phosphoric acid was 
added, and the final volume was adjusted to 200 mL 
with MilliQ water. Absorbance was recorded at 595 
nm. Release studies were conducted by incubating the 
tNGs with the encapsulated protein at different 
temperatures, following which, the released protein 
fraction was separated by a centrifugal filtering 
device. For this, 1 mL tNGs (10 mg/mL) containing 
FITC-BSA were placed in a Vivaspin 1000 kDa 
centrifugal filtering device, and centrifuged at certain 
time intervals, according to the manufacturer’s 
instructions. The filtrate solution was taken for 
analysis (absorbance recorded at 492 nm) while 
replacing it with a fresh buffer. 
Structural integrity and activity of etanercept  
Circular dichroism  
Circular dichroism (CD) spectra were recorded 
by using a Jasco J-810 spectropolarimeter (Jasco, 
Gross-Umstadt, Germany) equipped with a 
temperature controller (Jasco PTC-348W1 peltier 
thermostat) using 0.2 mm path length Quartz Suprasil 
cuvettes (Hellma, Müllheim, Germany). After 
background correction, spectra were averaged over 
three scans (λ = 195–240 nm; 0.5 nm intervals; 2 mm 
bandwidth; 4 s response time, 100 nm/min scanning 
speed). 
Etanercept–TNFα binding assay 
Following release and purification from tNGs 
(Vivaspin 500 MWCO 1000 kD, Sartorius, Göttingen, 
Germany), ETR concentration was determined by 
bicinchoninic acid assay (BCA) (Pierce™ BCA Protein 
Assay Kit, Thermo Scientific, Waltham, MA, USA). 
All samples were then adjusted to 10 ng/mL, and 
their TNFα binding affinity determined by a 
commercially available sandwich ELISA that 
incorporates plate bound TNFα (Sanquin, Diagnostic 
Services, Amsterdam, Netherlands). Results are 
expressed as the samples TNFα binding as a 
percentage of fresh ETR TNFα binding.  
Inflammatory skin equivalents and etanercept 
treatment 
Skin equivalent construction and ETR application 
Human skin equivalents were prepared from 
primary human keratinocytes and fibroblasts as 
previously described.[26, 34] Primary skin cells were 
derived from normal human skin with written 
consent. To induce skin inflammation, 20 ng/mL 
recombinant TNFα (eBioscience, Hatfield, UK) was 
supplemented into the skin equivalents growth media 
on days 10 and 12 of cultivation. ETR formulated in 
PBS (35 µg/cm2) or tNGs (35 µg/cm2 ETR; 350 µg/cm2 
tNG) was applied topically on days 11 and 13 and 
exposed to a temperature ramp (32–37 °C) over 3 h. 
On day 14, skin equivalents were halved and 





prepared separately for western blotting and 
immuno-histochemistry. 
Western Blotting 
Halved skin equivalents were lysed in RIPA 
buffer (supplemented with protease and phosphatase 
inhibitors) according to standard procedure. Protein 
content was quantified by BCA assay. Samples (15 µg 
protein) were then heated in SDS-PAGE buffer and 
separated by electrophoresis through a 
polyacrylamide gel (10%). Gels were blotted onto 
nitrocellulose membranes, blocked (5% 
skimmed-milk powder), exposed to primary 
antibodies (overnight, 4 °C), washed, incubated with 
horseradish peroxidise conjugated secondary 
antibodies (1 h, room temperature) and washed again. 
Blots were developed with ECL reagent (SignalFire™, 
Cell Signaling, Frankfurt/Main, Germany) and 
imaged by a PXi/PXi Touch gel imaging system 
(Syngene, Cambridge, UK). Antibodies were used at 
the following concentrations: 1:1000 anti-TNFα, 1:1000 
anti-TSLP, anti-ICAM1 1:2000, 1:500 anti-IgG Rabbit 
conjugated to horseradish peroxidase. 
Immunohistochemistry 
Halved skin equivalents were submerged in 
tissue freezing media, and flash frozen. Samples were 
subsequently cut into cross sections (8 µm) on a 
cryotome (Leica, PLACE) against the direction of tNG 
application (i.e., deep to superficial). Skin sections 
were fixed using a 4% formaldehyde solution, washed 
with PBS containing 0.0025% BSA and 0.025% Tween 
20 and blocked with goat serum (1:20 in PBS). 
Subsequently, skin sections were incubated overnight 
at 4 °C with primary antibodies. After washing, 
secondary antibodies were added for 1 h at room 
temperature, and finally skin sections were covered 
with antifading mounting medium. Images were 
analysed under a fluorescence microscope (BZ-8000, 
objectives 20x/0.75, zoom 10x, Plan-Apo, DIC N2, 
Keyence, Neu-Isenburg, Germany). Antibodies were 
used at the following concentrations: 1:500 anti-TNFα, 
1:500 anti-IgG Rabbit conjugated to Alexa 594. 
Immunological response of Langerhans cells 
after incubation with tNGs 
Monocyte derived Langerhans cells (MoLC) 
were generated from isolated human monocytes as 
described elsewhere.[35] Following seven days 
cultivation, MoLC were collected and characterized 
by surface expression of CD1a and CD207.[35] 
Afterwards, MoLCs were seeded into 24-well plates 
(2.5×105 cells/well) and incubated with tNGs (0.1 and 
0.5 mg/mL, with or without ETR load) for 24 h. The 
immunogenic effects of the tNGs were determined by 
the cell-surface expression CD83 and CD86 as 
described previously.[35] Additionally, cytotoxicity 
was measured by staining the cells with 
7-Aminoactinomycin D (7-AAD) (Sigma-Aldrich, 
Munich, Germany). Surface receptor expression and 
7-AAD penetration was assessed by flow cytometry 
(FACSCanto II, BD Biosciences, Heidelberg, 
Germany) and the resulting data analysed by FlowJo 
software (Treestar, Ashland, USA). 
Results and Discussion 
Synthesis and characterization of 
thermoresponsive nanogels formed by water 
in water thermo-nanoprecipitation 
The structural integrity of therapeutic proteins 
must be preserved when encapsulated within 
synthetic delivery vectors, as well as during their 
subsequent release, to ensure their biological activity. 
Moreover, the presence of certain substances 
originating from the initial synthesis procedure could 
strongly impact upon subsequent therapeutic action 
as a consequence of modification to protein structure 
or direct cellular toxicity. The encapsulation of 
proteins in crosslinked polymeric network is often 
performed in situ (i.e., during particle formation) to 
ensure efficient encapsulation. This requires very mild 
reaction conditions and above all bio-orthogonality 
towards the bioactive compound; elevated 
temperatures, the utilization of organic solvents and 
surfactants should all be avoided. Therefore, we were 
motivated to establish a modular approach to allow 
the in situ encapsulation of proteins in a framework of 
thermoresponsive nanogels. 
One of the most suitable methodologies for 
nanoparticle assembly from macromolecular 
precursor monomers is the nanoprecipitation 
technique.[21, 36, 37] This method is based on the 
injection of concentrated polymer solution into a 
non-solvent for the polymer that is also miscible with 
the polymer solvent. Our group has recently 
established a system where water held above the 
transition temperature of the corresponding 
thermoresponsive polymer could be used as a 
non-solvent.[38] Here we present an advanced 
approach: water in water thermo-nanoprecipitation 
(Figure 1). Given the temperature dependent 
solubility of thermoresponsive polymers, water could 
be used as both the polymer solvent and non-solvent. 
The macromolecular precursor molecules 
dPG-(BCN)8% and tPG-(N3)2 were solubilised in PBS, 
cooled in an ice bath, and then injected into PBS at 37 
°C. The Tcp of the tPG used here was tuned to occur at 
32 °C and as such, be fully soluble at 4°C. Exposure to 
temperatures > Tcp lead to polymer precipitation and 
the formation of precursor particles. Subsequently, 





upon the bioorthogonal crosslinking reaction between 
the strained alkyne and the azide functionalized 
precursor polymers, tNGs could be formed. 
Since the nanoprecipitation method is driven by 
the diffusion of the solvent into the non-solvent, the 
affinity of both dictates the diffusion rate and 
therefore the stability of the precursor suspension. 
The affinity of solvents towards each other (χ) can be 
described by the Hildebrand solubility parameter (𝛿𝛿), 
which in turn depends on temperature.[39] We 
believe that this dependency on temperature allows 
water at different temperatures to act as solvent and 
non-solvent for thermoresponsive polymers. 
Alternatively, the solvated polymer may precipitate 
upon the rapid heat transfer between the warm and 
the cold buffer solutions. 
One parameter affecting the formation of stable 
colloidal suspensions is the method by which both 
solvents are exposed to each other.[36] Several 
protocols were screened, including injection, 
dropwise addition of the non-solvent to the solvent, 
and slow heating of polymeric precursor solutions. Of 
these, the most reproducible formation of tNGs was 
achieved by injection of 1 mL polymer-PBS solution 
(30 mg/mL) held at 4 °C into 20 mL PBS held at 37 °C. 
The formation of the precursor particles is also known 
to be strongly dependent on the concentration of 
polymer in solvent.[40] Concentrations of 1–30 
mg/mL resulted in tNGs of comparable sizes and size 
distributions as confirmed by DLS, AFM and 
cryo-TEM analyses (Figure 2 a, b, c). This key 
parameter along with physiological reaction 
conditions allowed the co-precipitation of ETR, while 
retaining an unchanged tNG_tPG hydrodynamic 
diameter. Furthermore, NTA, which permits the 
determination of particle number, confirmed that 
increased polymer concentrations lead to 
proportional increases in the particle concentration, 
suggesting similar densities of tNG_tPG. 
 
 
Figure 1. Schematic representation of the water in water thermo-nanoprecipitation technique and the precursor macromolecules. ETR is co-precipitated during 
particle formation. 
 
Figure 2. Characterization of tNG_tPG. a) DLS, presented as size distributions by intensity, b) AFM height profile (scale bar 1 µm), 155.16 ± 22.14 nm, and c) 
cryo-TEM image (scale bar 200 nm). 





The skin penetration enhancing effects of two 
types of tNGs were assessed in the present study: tPG 
based tNGs synthesised as described above and 
pNIPAM based tNGs. Both use dPG as a 
macro-crosslinker to enable the growth of linear 
thermoresponsive polymers from a single core. The 
pNIPAM tNGs were synthesised by the 
well-established precipitation polymerization method 
from the acrylated dPG (dPG-Ac 10%) and NIPAM to 
achieve tNG of the desired size (Table S1). 
Encapsulation and release of etanercept by 
thermoresponsive nanogels 
Encapsulation of ETR or the model protein 
FITC-BSA was achieved by swelling the tNGs in a 
solution of the corresponding protein. For the 
tNGs_pNIPAM, this involved addition of the protein 
solution to the lyophilised NGs. As the tNG_tPG were 
handled and stored in concentrated solution, 
encapsulation was achieved by addition of 
concentrated protein solution above tNG Tcp and 
subsequent incubation together below the Tcp. The 
encapsulation of ETR in both types of tNGs had no 
obvious effect on the Tcp of the corresponding carrier 
(Figure 3 a). Moreover, encapsulation shielded the 
negative Zeta potential of ETR (approximately -17 
mV, 0.25 mg/mL) allowing the tNGs to retain their 
near neutral surface charges (Figure 3 b) [41]. 
Interestingly, the hydrodynamic diameter of both 
carriers remained unchanged upon encapsulation of 
ETR 10 wt. %. Together these data suggest efficient 
encapsulation of ETR within the crosslinked 
polymeric network of the tNGs. 
To estimate in vitro release kinetics, FITC-BSA 
was encapsulated in both types of tNG and incubated 
at different temperatures. Released FITC-BSA was 
then separated from the tNGs suspension and 
quantified by UV-Vis (Figure 4). In their swollen state 
(25 °C), the tNGs showed good protein retention with 
a release plateau of 14.7 ± 3.2 % and 22.3 ± 4.3 % for 
tNG_pNIPAM and tNG_tPG respectively after 8 h 
(19.7 ± 4.0 % and 34.9 ± 4.6 % respectively after 48 h). 
When exposed to temperatures above their Tcp, the 
rate of protein release from the tNG_tPG was instead 
sustained following 3 h incubation, reaching 89.9 ± 8.9 
% after 48 h. Above the Tcp of the tNG_pNIPAM, an 
immediate burst in protein release was seen, 
achieving 23.6 ± 5.6 % after just 1 h compared to 9.5 ± 
5.3% below the Tcp. A plateau was then seen between 
3 and 8 h, following which a linear phase of protein 
release was seen, achieving 82.4 ± 5.6 % after 48 h. 
 
 
Figure 3. a) Normalised transmission of the tNGs aqueous solutions as a function of temperature UV-Vis (λ = 500 nm). b) Zeta potential and size of ETR and tNGs. 
 
Figure 4. Cumulative release of FITC-BSA from tNG_pNIPAM and tNG_tPG at 25 °C and 37 °C. Inset shows release profiles over the first 4 h. 





To ensure the structural stability of ETR within 
the tNGs, CD measurements were performed (Figure 
5). Thermal denaturation of the protein was observed 
to occur at temperatures ≥ 45 °C, in line with previous 
literature [41, 42]. Therefore the mild reaction 
conditions in which the tNG_tNGs are synthesised 
(temperatures do not exceed 37 °C) will enable ETR 
encapsulation during tNG_tPG formation without 
loss of structural integrity, as well as by temperature 
induced swelling of pre-formed tNGs. Indeed, the CD 
spectra of encapsulated ETR in both types of tNGs 




Figure 5. CD spectra of a) ETR measured at different temperatures. b) ETR 
encapsulated in tNG_pNIPAM, c) ETR encapsulated in tNG_tPG. 
 
Previous literature has demonstrated 
encapsulation of proteins within tNGs better 
preserves their biological activity following release 
after long term storage.[12] Similar results for ETR 
have also been described following encapsulation in 
synthetic carriers.[43] An ELISA based assay of TNFα 
binding by ETR was performed following 0, 2 and 4 
weeks storage at room temperature for ETR held in 
solution or encapsulated within tPG or pNIPAM 
based tNGs (Figure 6). While a significant decrease in 
TNFα binding was seen by the fourth week for ETR in 
PBS, the binding activity of ETR encapsulated in both 
tNG chemistries appeared stable throughout the 
tested duration. This is perhaps the result of weak 
interactions between ETR molecules and the 
encapsulating chemistries when concentrated within 
the tNG, acting to stabilise protein structure and 
shield them from environmental factors. Similarly, 




Figure 6. ETR–TNFα binding assay following 0 (black), 2 (grey) and 4 (white) 
weeks storage at room temperature. Statistical differences were calculated by 
multiple Student’s t -test (error bars = SEM; * = p ≤ 0.5). 
 
Thermoresponsive nanogel mediated 
etanercept delivery to inflammatory skin 
equivalents  
To assess the ability of the tNGs to deliver ETR 
past the SC and any local anti-inflammatory effects 
that result from this, penetration studies were 
performed in living human-based skin equivalents. In 
recent years, the importance of human-based model 
systems for basic and preclinical research has been 
increasingly recognised. In biomedical research of the 
skin and inflammatory diseases, results obtained from 
animal models have often held poor predictive value 
for humans owing to gross anatomical and 
physiological differences.[44, 45] Ultimately, this has 
resulted in a high rate of failure in the translation from 
preclinical to clinical studies.[46] For the testing of 
human-based biologicals such as ETR, animal studies 
appear even less adequate given the immediate 





immune responses experienced upon administration 
of macromolecules derived from other species. 
Moreover, major concerns over the suitability of 
established models for assessing drug related effects 
were recently raised, in particular, the widely used 
imiquimod-induced murine psoriasis model. To 
induce an inflammation-like state, normal skin 
equivalents were supplemented with TNFα, a key 
mediator of plaque psoriasis and chronic atopic 
dermatitis.[28] As previously reported, this 
recapitulates several key features of inflammatory 
skin disease including hyperkeratosis, increased 
release of pro-inflammatory cytokines and 
unphysiologically high skin surface pH.[26, 27] 
However the reader should note the addition of TNFα 
alone to skin equivalents devoid of immune cells 
cannot fully emulate the complexity of the in vivo 
conditions.[47] 
ETR in PBS alone or in tNGs was applied directly 
to the surface of skin equivalents 24 h after TNFα 
treatment (days 11 and 13) and exposed to a 
temperature gradient to simulate the natural 
temperature gradient of human skin (32–37 °C over 3 
h) (Figure 7). On day 14, models were processed for 
immunohistochemical and western blot analyses. 
Application of tNG resulted in high ETR 
concentrations throughout the SC and apparent 
penetration into the VE (Figure 8). The effect was 
more pronounced in tNG_pNIPAM treated 
equivalents. In this regard, it is interesting to note the 
release kinetics from protein loaded tNG_pNIPAM at 
37 °C markedly exceeded those of protein loaded 
tNG_tPG over the first hour of incubation (Figure 4). 
When applied in PBS, ETR failed to penetrate into the 
VE (Figure 8a). Though no quantitative measurements 
were made here, the effective delivery of ETR into the 
TNFα treated equivalents by the tNGs but not PBS 
shows the requirements for a potent delivery 
system.[48] Notably, the ability of tNG encapsulated 
ETR to overcome the SC suggests the presence of a 
moderate barrier deficiency similar to that observed 
in psoriasis and atopic dermatitis—in which 
enhanced skin permeabilities are characteristic—as 
well as other disease modelling skin equivalents.[12, 
26, 49-51] Previous work from our group has 
demonstrated the effective tNG_pNIPAM mediated 
delivery of BSA (~68 kDa), Asparaginase ~140 kDa) 
and Transglutaminase 1 (~89 kDa) into the VE of tape 
stripped porcine skin, filaggrin knockdown skin 
equivalents, and transglutaminase 1 knock-down skin 
equivalents respectively, all models of 
barrier-deficient skin.[12, 52] Notably, protein 
delivery to the viable layers of barrier intact skin was 
not possible. ETR (~150 kDa) is the largest protein yet 
to be effectively delivered to the VE of skin 
equivalents by tNG_pNIPAM and the first 
demonstration that protein loaded tNGs_tPG can 
achieve similar results. It is, however, notable that the 
permeability of skin equivalents to certain 
compounds is inherently greater than found in vivo. 
To address whether protein delivery is also possible 
in barrier deficient human skin, FITC-BSA loaded tPG 
and pNIPAM tNGs were applied onto tape stripped, 
excised human skin (Figure S1). Concordant with the 
data from the skin equivalents, protein penetration 
through the SC and into the VE were apparent. 
 
 
Figure 7. Experimental setup: ETR is encapsulated in tNG_pNIPAM or tNG_tPG by letting them swell in a solution of ETR, below the clouding point. Following, the 
tNGs are applied on reconstructed human skin (RHS) equivalents treated with TNFα (day 11 and 13) and incubated in a temperature gradient of 32-37 °C over 3 h, 
simulating the natural temperature gradient of human skin. 






Figure 8. Representative immunohistochemical staining against ETR in skin equivalents topically treated with ETR dissolved in PBS (a) or encapsulated in 
tNG_pNIPAM (b) or tNG_tPG (c). Images show pseudo coloured ETR temperature staining (scale and direction of increasing signal intensity shown on the right) 
overlaid onto differential interference contrast (DIC) images, onto which the boundaries between the stratum corneum / viable epidermis (upper) and the viable 
epidermis / dermis (lower) have been marked (scale bar = 50 µm). Protein levels of TNFα, TSLP and ICAM1 in TNFα treated skin equivalents (black) calculated as a 
percentage of normal skin equivalents (grey) (d). Protein levels of TNFα (e), TSLP (f) and ICAM1 (g) in TNFα treated skin equivalents following treatment with empty 
(grey) or ETR loaded (black) tNGs or PBS. Values are expressed as a percentage of TNFα treated controls. Insets show representative western blots from the protein 
of interest, above, and β actin, below. Dashed lines indicate mean protein levels found in untreated, normal skin equivalents. Statistical differences from the normal 
controls (d) or TNFα treated controls (e-f) were calculated by Student’s t -test (n = 3, error bars = SEM, * = p ≤ 0.05).  
 
The precise mechanism by which the tNGs are 
able to deliver proteins past the SC is not entirely 
clear. When FITC-BSA loaded in tNG based on 
p(N-isopropylmethacrylamide) (pNIPMAM) (Tcp = 
47 °C) were applied to tape stripped skin, little to no 
penetration past the SC was observed (Figure 
S1a).[53] This indicates the temperature triggered 
release of protein, water, and/or heat induced 
conformational changes to the tNG structure are 
essential to the observed protein penetration into the 
skin. Indeed, we saw evidence that protein entered 
the VE of TNFα treated equivalents alone, while the 
tNGs remained exclusively in their SCs (Figure S2), 
concordant with other published data. 
In a previous study, ultrastructural analyses of 
the SCs of skin biopsies following 2 h tNG_tPG 
exposure revealed clear disordering and/or swelling 
within the comprising structural components, as well 
as apparent dilations of the spaces between these.[54] 
This was strongly suggestive of an enhanced state of 
hydration within the SC.[55] It was also demonstrated 
that lipid to protein ratios found within the SC were 
increased following application of tNG_tPG and, to a 
lesser extent, tNG_pNIPAM. Thus, the penetration 
enhancing effects of the tNG correlated well with their 
ability to re-organise the SC, possibly forming 
transient pathways along which molecules may 
diffuse, a hypothesis that could rightly be applied to 
the present study. While we have demonstrated the 
necessity of skin barrier impairment and triggered 
protein/water release from the tNGs for effective 
protein delivery (Figure S1), the significance of 
protein release profiles from tNGs on the skin surface 
and/or in the SC will require more thorough 
quantitative investigations. It is however notable that 
the tNG tested here and elsewhere appear to show an 
innate ability to penetrate into the SC, or to interfere 
with its structural ordering, and that release from 
within the SC could significantly improve the 
penetration of proteins.[54] Future exploration of 
factors such as cross-linking density, rigidity, charge 
and hydrophilicity may prove insightful with regard 
to the SC penetrating properties of tNGs.[54, 56, 57] 
In TNFα derived skin inflammation, 
keratinocytes of the VE are known to release several 
cytokines including thymic stromal lymphopoietin 
(TSLP) [49] and further TNFα. [58, 59] They also 
up-regulate cell surface receptors such as intercellular 
adhesion molecule 1 (ICAM1), a leukocyte adhesion 
molecule that plays a key role in plaque psoriasis.[60] 
Western blot analysis confirmed TNFα application 
induced similar responses in our skin equivalents 
(Figure 8d). Topical application of ETR in 
tNG_pNIPAM produced significant reductions in all 





three proteins relative to TNFα treated skin 
equivalents, achieving levels found in the untreated 
skin equivalents (Figure 8e-g). Similar reductions in 
TNFα and TSLP levels were achieved following 
application of ETR in tNG_tPG. Interpretation of these 
results is, however, complicated by the apparent 
effects of the vehicle controls. For instance, 
application of PBS alone produced significant 
decreases in TSLP and ICAM1 levels, perhaps a result 
of water permeation into the equivalents and 
subsequent dilution of the extracellular environment 
in the VE.[1] Indeed, previous evidence has shown 
skin dehydration is associated with the upregulation 
of pro-inflammatory markers.[61] Though 
non-significant, deviations are also apparent for 
equivalents treated with empty tNGs. This may again 
relate to altered water contents within the skin 
equivalents, structural changes induced by tNGs, or 
occlusive effects induced by tNG presence on the 
equivalent’s surface.[54] Nevertheless, the impact of 
ETR is clear, wherein its delivery by the tNGs 
correlated with the strongest and most consistent 
anti-inflammatory effects on the skin equivalents as is 
particularly notable in TSLP levels. Moreover, 
delivery of ETR in PBS results in less pronounced 
effects than applications of PBS alone, perhaps owing 
to the higher osmotic potential of the equivalents 
surface when proteins are applied. This highlights the 
particular effect tNG mediated ETR delivery has and 
suggests a mechanism that involves more than simple 
skin hydration. 
Though we saw no robust evidence of tNG 
penetration past the SC in our skin equivalents at our 
tested time-points and concentrations, there is some 
evidence that this may be possible in ex vivo human 
skin, and that very small amounts of tNGs are actively 
taken up by dendritic cells of the VE, something that 
could prove valuable to the treatment of 
inflammatory skin diseases.[62, 63] 
Immunogenicity  
The human skin is a highly immunologically 
active organ. Many immune cells, such as Langerhans 
cells (LCs), reside and function as sentinels for 
potential harmful xenobiotics. Notably, proteins are 
also highly immunogenic and topical application of 
proteins requires a careful assessment of potential 
immunological activations that would limit their 
applicability. Additionally, interactions between tNGs 
and immune cells of the skin cannot be excluded. To 
date, it has been shown that both tNG_pNIPAM and 
tNG_tPG induce no specific toxicity in murine LC’s or 
human keratinocytes.[63, 64] However, a lack of 
cytotoxicity does not exclude immunogenicity. 
Though nanoparticle induced immunogenicity is 
desirable in certain instances -vaccine formulations 
for example[65, 66] - further immune cell activation in 
inflammatory skin diseases is not.[67] Indeed, the bio- 
and immune- compatibility of the tNGs towards skin 
LCs is essential to their use in the topical treatment of 
a wide range of skin diseases. 
Monocyte derived LCs (MoLC) were used to 
determine the bio- and immune- compatibility of the 
empty and ETR-loaded tNGs. Upon immunological 
activation, immature MoLC elevate surface 
expression of CD86 and CD83. Expressions of these 
markers were measured by flow cytometric analysis 
as an assay of immunogenicity. Following incubation 
with loaded and unloaded tNG_pNIPAM and 
tNG_tPG, as well as ETR in solution, the expressions 
of CD86 and CD83 were not significantly altered 
(Figure 9a, b). In addition, 7-AAD, a cell membrane 
impermeable dye, was used to assess MoLC viability, 
and demonstrated no cytotoxic induction (Figure 9c). 
 
 
Figure 9. Expression of the activation markers (a) CD86 and (b) CD83 of MoLCs after 24 h incubation with unloaded and ETR-loaded tNGs and ETR in PBS (grey 
= 0.05 mg/mL ETR, black = 0.5 mg/mL ETR). (c) Cytotoxic induction in MoDCs, as measured by 7-AAD exclusion. Statistical differences from untreated control were 
calculated by one way ANOVA with Dunnett’s correction for multiple comparisons (n = 3, error bars = SEM, ** = p ≤ 0.01).  






This proof–of-concept study holds major 
implications for tNG production as well as high 
throughput protein encapsulation strategies. 
Potentially, the herein presented methodology could 
be adapted for the fabrication of tNGs from a library 
of various thermoresponsive polymers. To the best of 
our knowledge, it is also the first strategy to show 
local anti-inflammatory activity within skin following 
topical protein application. Compared to systemic 
routes, topical administration of proteinaceous 
biologicals could prove advantageous in several 
regards: improved therapeutic targeting against 
dermatological conditions, reductions in off target 
effects and reductions in the therapeutic doses 
required of these costly therapies.  
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